Pharmaceuticals News and Research

RSS

Iclusig gets FDA approval for two rare blood and bone marrow diseases

The U.S. Food and Drug Administration today approved Iclusig (ponatinib) to treat adults with chronic myeloid leukemia and Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL), two rare blood and bone marrow diseases.

15 Dec 2012

Fluidigm, GIS announce establishment of first single-cell genomics research center in Asia

The Genome Institute of Singapore (GIS), an institute under the umbrella of the Agency for Science, Technology and Research, and Fluidigm Corporation today announced the establishment of the first research center in Asia exclusively dedicated to accelerating the understanding of how individual cells work, and how diagnosis and treatment might be enhanced through insight derived from single cells.

15 Dec 2012

MDx, Amarantus sign license agreement for LymPro Alzheimer's disease diagnostic blood test

Amarantus BioScience, Inc., a biotechnology company discovering and developing treatments for diseases associated with protein misfolding and apoptosis, today announced that it has licensed the LymPro Alzheimer's Disease Diagnostic Blood Test (LymPro) from Memory Dx, LLC (MDx), formerly known as Provista Life Sciences, Inc.

14 Dec 2012

FDA grants accelerated approval to ARIAD’s Iclusig for treatment of CML, Ph+ ALL

ARIAD Pharmaceuticals, Inc. today announced that following a priority review, the U.S. Food and Drug Administration (FDA) has granted accelerated approval of Iclusig (ponatinib) for the treatment of adult patients with chronic, accelerated or blast phase chronic myeloid leukemia (CML) that is resistant or intolerant to prior tyrosine kinase inhibitor (TKI) therapy or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) that is resistant or intolerant to prior TKI therapy.

14 Dec 2012

NCC to expand women's cancer programs in the developing world

The National Cancer Coalition (NCC) is expanding its efforts to fight women's cancers in the developing world.

14 Dec 2012

Malaria vaccine trial: an interview with Professor Sir Brian Greenwood

Malaria is an infection caused by a parasite called plasmodium, which is transmitted from person to person by females of some species of mosquito. It is primarily a disease of tropical countries.

14 Dec 2012

Dr. Reddy's Laboratories launches public offer to acquire OctoPlus shares

Dr. Reddy's Laboratories Limited, together with its subsidiaries, launches the recommended public offer to acquire all the issued and outstanding shares of OctoPlus N.V., a service-based specialty pharmaceutical company, at an offer price of EUR 0.52 (cum dividend) per share.

14 Dec 2012

Viewpoints: Politicians flirting with danger on Medicare eligibility age; Maybe doctors should be paid less

The 2010 health- care law, which imposed immediate and heavy cuts on hospitals, drugmakers and insurers, left doctors relatively untouched. A 1997 law that reduces doctors' Medicare payments is consistently overridden by Congress.

14 Dec 2012

Pfizer, Ligand announce FDA acceptance of bazedoxifene/conjugated estrogens NDA

Pfizer Inc. and Ligand Pharmaceuticals Incorporated today announced that the United States Food and Drug Administration (FDA) accepted for review a New Drug Application (NDA) for bazedoxifene/conjugated estrogens (BZA/CE), a potential new medicine for non-hysterectomized women for the treatment of moderate-to-severe vasomotor symptoms (VMS) and vulvar and vaginal atrophy (VVA) associated with menopause, as well as the prevention of postmenopausal osteoporosis.

14 Dec 2012

Top-line results from AstraZeneca’s fostamatinib Phase IIb monotherapy study on RA

AstraZeneca today announced top-line results of OSKIRA-4, a Phase IIb monotherapy study of fostamatinib, the first kinase inhibitor with selectivity for SYK (spleen tyrosine kinase) in development as an oral treatment for rheumatoid arthritis (RA).

13 Dec 2012

Fatal imbalance between global disease burden and drug development

Despite important progress in research and development (R&D) for global health over the past decade, only a small fraction of new medicines developed between 2000 and 2011 were for the treatment of neglected diseases, highlighting the 'fatal imbalance' between global disease burden and drug development for some of the world most devastating illnesses, said Doctors Without Borders/M-decins Sans Fronti-res (MSF) and the Drugs for Neglected Diseases initiative (DNDi), in an analysis to be presented today at an international conference aimed at spurring medical innovations for these diseases.

13 Dec 2012

New way to effectively make designer drugs that hit collections of protein targets simultaneously

An international research collaboration led by scientists at the University of North Carolina School of Medicine and the University of Dundee, in the U.K., have developed a way to efficiently and effectively make designer drugs that hit multiple protein targets at once.

13 Dec 2012

Heartbeat Experts announces increased revenue and expanded clients in emerging markets

Heartbeat Experts, the global leader in stakeholder management solutions for the life sciences industry, announced today increased revenue and expanded clients across Brazil, Russia, China, India and Korea. Heartbeat Experts' reported combined revenue from these markets grew 50% in the third quarter of 2012.

13 Dec 2012

TSEC strategy can benefit postmenopausal women

Investigators at Wake Forest Baptist Medical Center have concluded research on a new postmenopausal hormone therapy that shows promise as an effective treatment for menopausal symptoms and the prevention of osteoporosis without increasing the risk for heart disease or breast cancer.

13 Dec 2012

Syrian conflict destroying country's health care system

"The nearly two-year conflict in Syria has taken tens of thousands of lives, destroyed entire neighborhoods and sent hundreds of thousands of people fleeing. But more quietly, it has also eaten away at the country's health care system," IRIN reports.

12 Dec 2012

AstraZeneca, Case Western Reserve initiate AZD5847 Phase 2a trial in TB

Case Western Reserve University School of Medicine and AstraZeneca, a global biopharmaceutical company, today announced the first patient enrolled in a Phase 2a trial to assess the effectiveness of AZD5847, a new test drug for patients with tuberculosis (TB), including patients with HIV co-infection.

12 Dec 2012